TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1932648

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus, followed by 2 mg/min infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (saline bolus and infusion)
Number of subjects: 22
Study: 7048827

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Truncal vagotomy (TV)
Number of subjects: 106
Study: 31387574

Group type: EXPERIMENTAL
Intervention: Magnesium-based compression screws
Number of subjects: 190

Group type: COMPARATOR
Intervention: Titanium Herbert screws
Number of subjects: 190
Study: 27621144

Group type: EXPERIMENTAL
Intervention: New tool with colored scales and target range indicator (TRI)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Colors tool
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Smiley icons tool
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TRI tool
Number of subjects: 140
Study: 26348767

Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) intake (450 mg bi-daily for 1 month)
Number of subjects: 100
Study: 25798493

Group type: EXPERIMENTAL
Intervention: Community-doula home-visiting intervention
Number of subjects: 0
Study: 23204355

Group type: EXPERIMENTAL
Intervention: Moral identity group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-moral identity group
Number of subjects: 94
Study: 19732408

Group type: EXPERIMENTAL
Intervention: Regular adherence counseling
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Regular counseling plus a calendar
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Regular counseling and a treatment assistant
Number of subjects: 621
Study: 17721407

Group type: EXPERIMENTAL
Intervention: Welling scale rating by six independent raters
Number of subjects: 12
Study: 15707190

Group type: EXPERIMENTAL
Intervention: Community-randomised trial to improve maternal health
Number of subjects: 0
Study: 12608650

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ) treatment for one year
Number of subjects: 10
Study: 9632382

Group type: EXPERIMENTAL
Intervention: Small-group, seven-session HIV risk reduction program
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Intervention condition (men from STD clinics)
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Intervention condition
Number of subjects: 3706
Study: 8080380

Group type: EXPERIMENTAL
Intervention: Transabdominal preperitoneal laparoscopic hernia repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open tension-free repairs using a polypropylene mesh
Number of subjects: 100
Study: 2792658

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol administration (0.15 g/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral ethanol administration (0.15 g/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intraduodenal ethanol administration (0.15 g/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gastrectomy (Billroth II subtotal)
Number of subjects: 15
Study: 1017533

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betamethasone valerate ointment
Number of subjects: 20
Study: 30277987

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 28632742

Group type: EXPERIMENTAL
Intervention: Serum uric acid increment (standard deviation) among individuals with normoglycaemia
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Serum uric acid among normoglycaemic women
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Serum uric acid among normoglycaemic men
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Serum uric acid among prediabetic men
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Serum uric acid among prediabetic women
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Serum uric acid increment (standard deviation) among individuals with prediabetes
Number of subjects: 8367
Study: 26314688

Group type: EXPERIMENTAL
Intervention: Prostar XL
Number of subjects: 3138

Group type: COMPARATOR
Intervention: Perclose ProGlide
Number of subjects: 3138
Study: 23617482

Group type: EXPERIMENTAL
Intervention: Dual-energy subtraction
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD) alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Combination of bone suppression and CAD
Number of subjects: 143

Group type: COMPARATOR
Intervention: Original nonenhanced conventional chest radiograph
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Dual-energy subtraction and bone suppression
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: CAD program
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 143
Study: 21518596

Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg/d)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nadroparin (0.1 ml/10 kg q12 h)
Number of subjects: 300
Study: 18812757

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (high-Dk)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etafilcon A (low-Dk)
Number of subjects: 20
Study: 17137026

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice a day intravenously and then orally, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam 4 g/0.5 g three times a day, combined with amikacin 7.5 mg/Kg twice a day for a maximum of 14 days.
Number of subjects: 47
Study: 12924687

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in a group format, 14 sessions, small groups of 4 to 6 participants
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 52
Study: 10680039

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (Fragmin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8684876

Group type: EXPERIMENTAL
Intervention: One injection of Oka/Merck varicella vaccine
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Two injections of Oka/Merck varicella vaccine
Number of subjects: 2000
Study: 1654074

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (further six courses)
Number of subjects: 369

Group type: COMPARATOR
Intervention: No maintenance chemotherapy
Number of subjects: 369
Study: 6222858

Group type: EXPERIMENTAL
Intervention: Moxalactam (10 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefazolin (10 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moxalactam and Cefazolin
Number of subjects: 20
Study: 31925817

Group type: EXPERIMENTAL
Intervention: P218 (10 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (30 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (100 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (250 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (500 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (750 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (1000 mg)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: P218 (250 mg) with food
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 31401653

Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg/d)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Post-treatment effects
Number of subjects: 1021
Study: 27464960

Group type: EXPERIMENTAL
Intervention: Inhaled allergens
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Food allergens
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Ubiquitous respiratory allergens (grass, olive/ash pollen, house dust mites)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Regionally occurring pollen allergens (ragweed, birch, cypress)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Airborne allergens cross-reacting with food allergens
Number of subjects: 340
Study: 26147820

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intranasal midazolam as premedication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 60
Study: 24345173

Group type: EXPERIMENTAL
Intervention: Motivation (increased as anticipated reward decreased)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expected reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report ratings
Number of subjects: 0
Study: 23529993

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1200 mg n-3 long chain polyunsaturated fatty acids)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 19077149

Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry (LDF) used to assess bone vascularity during implant insertion.
Number of subjects: 23
Study: 17726273

Group type: EXPERIMENTAL
Intervention: 100 mg levodopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15342261

Group type: EXPERIMENTAL
Intervention: Adults using lexical and referential information in sentence processing
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Five-year-old children using verb biases in sentence processing
Number of subjects: 2
Study: 11133211

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 809

Group type: COMPARATOR
Intervention: Carotid intima-media thickness
Number of subjects: 809

Group type: COMPARATOR
Intervention: Femoral intima-media thickness
Number of subjects: 809

Group type: COMPARATOR
Intervention: Carotid plaques
Number of subjects: 809

Group type: COMPARATOR
Intervention: Femoral plaques
Number of subjects: 809
Study: 11367872

Group type: EXPERIMENTAL
Intervention: Test formulation (T) 3 x 150 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (R) 3 x 150 mg
Number of subjects: 24
Study: 9438894

Group type: EXPERIMENTAL
Intervention: Lidocaine 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lidocaine 200 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 21
Study: 8288408

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily, n = 52; 50 mg twice daily, n = 16)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Diltiazem (90 mg three times daily, n = 50; 60 mg three times daily, n = 16)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 146
Study: 3688125

Group type: EXPERIMENTAL
Intervention: Keeping stationery
Number of subjects: 43

Group type: COMPARATOR
Intervention: Not keeping stationery
Number of subjects: 43
Study: 30539839

Group type: EXPERIMENTAL
Intervention: Appleby operation
Number of subjects: 17
Study: 26613820

Group type: EXPERIMENTAL
Intervention: Clomifene citrate (100mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Letrozole (5mg daily for 5 days), metformin (850mg), and pioglitazone (15mg for 10 days)
Number of subjects: 100
Study: 24695986

Group type: EXPERIMENTAL
Intervention: BQ-123 (400 nmol/min)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22441270

Group type: EXPERIMENTAL
Intervention: Auriculotherapy with needles
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Auriculotherapy with seeds
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study: 20083625

Group type: EXPERIMENTAL
Intervention: Beta-blocker (metoprolol succinate)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1200
Study: 18419890

Group type: EXPERIMENTAL
Intervention: Decentralised TB services at township hospitals
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control groups (township hospitals referring to county TB dispensaries)
Number of subjects: 171
Study: 16162465

Group type: EXPERIMENTAL
Intervention: Descriptive self-care health book
Number of subjects: 1967

Group type: EXPERIMENTAL
Intervention: Decision-tree based self-care health book
Number of subjects: 1967

Group type: COMPARATOR
Intervention: No-book control condition
Number of subjects: 1967
Study: 14569643

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 208
Study: 10383563

Group type: EXPERIMENTAL
Intervention: OROS amitriptyline (75 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: IR amitriptyline (25 mg every 8 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: IR amitriptyline (3x25 mg at nighttime)
Number of subjects: 14
Study: 8696988

Group type: EXPERIMENTAL
Intervention: Septic patients with organ dysfunction (OD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Septic patients without organ dysfunction (OD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Postgastrectomy patients
Number of subjects: 49
Study: 2060151

Group type: EXPERIMENTAL
Intervention: Iodide supplementation (500 micrograms/day for 28 days)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 29736491

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (RM-GIC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 18
Study: 27064959

Group type: EXPERIMENTAL
Intervention: Head turn preference
Number of subjects: 70
Study: 25154949

Group type: EXPERIMENTAL
Intervention: Proximal insertion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Distal insertion
Number of subjects: 44
Study: 22646230

Group type: EXPERIMENTAL
Intervention: Intensive glycemia intervention (goal A1C <6.0%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard glycemia intervention (goal A1C 7‐7.9%)
Number of subjects: 0
Study: 20439595

Group type: EXPERIMENTAL
Intervention: Concomitant administration of Gardasil, Menactra, and Adacel (group A)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Nonconcomitant administration of Gardasil, Menactra, and Adacel (group B)
Number of subjects: 1042
Study: 18161643

Group type: EXPERIMENTAL
Intervention: Post-discharge telephone intervention to encourage compliance with aftercare
Number of subjects: 282
Study: 16906786

Group type: EXPERIMENTAL
Intervention: Once-daily regimen of efavirenz, emtricitabine and tenofovir DF (administered as individual agents)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Co-formulated efavirenz/emtricitabine/tenofovir DF
Number of subjects: 517
Study: 12707093

Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose doxycycline (20-mg tablets taken twice daily for 6 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 11123824

Group type: EXPERIMENTAL
Intervention: Praziquantel at 60 mg/kg divided into two doses
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Praziquantel at a single dose of 40 mg/kg
Number of subjects: 253
Study: 9181384

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (A/C) 70/10 mg/kg/day given b.i.d.
Number of subjects: 463

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (A/C) 60/15 mg/kg/day given t.i.d.
Number of subjects: 463
Study: 8233391

Group type: COMPARATOR
Intervention: Argon laser scatter (panretinal) photocoagulation
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Krypton laser scatter (panretinal) photocoagulation
Number of subjects: 696
Study: 2418659

Group type: EXPERIMENTAL
Intervention: Bleomycin intravesical instillation (60 mg on each treatment day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bleomycin + Bestatin (60 mg per day)
Number of subjects: 124
Study: 31849295

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (569 patients)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Platelet function testing (PFT)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Type 2 myocardial infarction (T2MI)
Number of subjects: 750
Study: 30201679

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) intervention implemented in family medicine clinics
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (general internal medicine clinics)
Number of subjects: 71
Study: 26253874

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 90

Group type: COMPARATOR
Intervention: No Amiodarone
Number of subjects: 90
Study: 25403709

Group type: EXPERIMENTAL
Intervention: Individualised dietetic advice and regular weekly follow-up (INT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (SC) with provision of nutrition education materials only
Number of subjects: 120
Study: 21935656

Group type: EXPERIMENTAL
Intervention: Low pulse pressure in patients with Killip Class II‐IV heart failure
Number of subjects: 1955
Study: 19798046

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 18
Study: 18521509

Group type: EXPERIMENTAL
Intervention: activated prothrombin complex concentrate (aPCC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: recombinant factor VIIa (rFVIIa)
Number of subjects: 48
Study: 15688388

Group type: EXPERIMENTAL
Intervention: Automation-assisted screening
Number of subjects: 471297

Group type: COMPARATOR
Intervention: Conventional screening
Number of subjects: 471297
Study: 12219472

Group type: COMPARATOR
Intervention: Combination of antioxidants and zinc
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Photodynamic treatment of certain forms of CNV
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Prophylactic laser treatment of soft drusen maculopathy
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Visual rehabilitation using eccentric viewing
Number of subjects: 3600
Study: 9926184

Group type: EXPERIMENTAL
Intervention: Tramadol (3.0 mg.kg‐1)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.3 mg.kg‐1)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Saline (0.2 ml.kg‐1)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Pethidine (1.5 mg.kg‐1)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 281
Study: 7486039

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 60 s (Pilot Group A, n = 5)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 30 s (Pilot Group B, n = 5)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.10 mg/kg, 2 x ED95) administered over 5-10 s (Group C, n = 30)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vecuronium (0.10 mg/kg, 2 x ED90) administered over 5-10 s (Group D, n = 30)
Number of subjects: 70
Study: 2208633

Group type: EXPERIMENTAL
Intervention: albendazole 400mg/d x 3d
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: albendazole 400mg/d x 5d
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: pyrantel 1,500mg/d x 3d
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: pyrantel 1,500mg/d x 5d
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: albendazole 400mg/d x 3d or 5d
Number of subjects: 720
Study: 6161273

Group type: EXPERIMENTAL
Intervention: vinblastine/bleomycin
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: adriamycin/cis-dichlorodiammineplatinum (II) (DDP)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: surgical removal of residual pulmonary metastases
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: complete responders
Number of subjects: 74

Group type: COMPARATOR
Intervention: all other patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: overall survival
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: advanced abdominal disease, elevated beta-HCG, LDH, extension of pulmonary disease
Number of subjects: 74
Study: 31182874

Group type: EXPERIMENTAL
Intervention: Pregabalin (1 mg/kg of weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28743341

Group type: EXPERIMENTAL
Intervention: Abdominal aorta pressure group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 25494869

Group type: EXPERIMENTAL
Intervention: Endurance training only (E)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endurance and strength training (E+S)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Endurance training only (E) and Endurance and strength training (E+S)
Number of subjects: 27
Study: 23494656

Group type: EXPERIMENTAL
Intervention: rhLAMAN (recombinant human alpha-mannosidase) administered weekly via intravenous enzyme replacement therapy (ERT) for 12 months
Number of subjects: 10
Study: 21644300

Group type: EXPERIMENTAL
Intervention: Tongluo Guben needling method (observation group)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (Shenshu, Dachangshu, Huantiao, Chengfu)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both groups (VAS and ODI scales)
Number of subjects: 132
Study: 19607770

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Number of subjects: 0
Study: 16424422

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: R-albuterol
Number of subjects: 14
Study: 12814158

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler (Symbicort Turbuhaler) 160/4.5 microg delivered dose, two inhalations bid
Number of subjects: 321

Group type: COMPARATOR
Intervention: Budesonide plus formoterol via separate inhalers
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol single inhaler (Symbicort Turbuhaler)
Number of subjects: 321
Study: 10608768

Group type: EXPERIMENTAL
Intervention: 25 microg/kg of recombinant human (rh) IL‐10
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 49
Study: 8858433

Group type: EXPERIMENTAL
Intervention: Three group discussion sessions
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Three sessions of caring for a PWA
Number of subjects: 3

Group type: COMPARATOR
Intervention: Assessment materials only
Number of subjects: 3